Rituximab is a monoclonal antibody that binds CD20 and induces complement-mediated lysis, as well as direct cytotoxicity and apoptosis.

利妥昔单抗是一种单克隆抗体，与CD20结合，诱导补体介导的分解作用，以及直接的细胞毒性和凋亡。

One candidate drug aiming to suppress ngf was a monoclonal antibody called tanezumab, owned by Pfizer, an American pharmaceutical firm.

一种旨在抑制 ngf 的候选药物是一种名为 tanezumab 的单克隆抗体，由美国制药公司辉瑞公司拥有。